CARL ALLEN to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications CARL ALLEN has written about TOR Serine-Threonine Kinases.
Connection Strength
0.156
-
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5).
Score: 0.118
-
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
Score: 0.039